← Back to Companies

VedaBio

Biotechnology company revolutionizing molecular biology with a breakthrough platform for near-instant molecular detection of multiplexed analytes, delivering best-in-class accuracy without the need for target amplification.

Location
New Haven, Connecticut, USA
Founded
2021
Investors
1
Categories
molecular-diagnostics, diagnostics, biotech, point-of-care

Notes

VedaBio is a biotechnology company revolutionizing molecular biology with its breakthrough platform for near-instant molecular detection. The company is headquartered in New Haven, Connecticut.

The company's technology enables:

  • Near-instant detection of multiple molecular targets
  • Best-in-class accuracy without target amplification (no PCR required)
  • Multiplexed analyte detection
  • Point-of-care applications

By eliminating the need for target amplification, VedaBio's platform can provide results much faster than traditional PCR-based methods while maintaining high accuracy. This has significant implications for:

  • Infectious disease diagnostics
  • Point-of-care testing
  • Time-sensitive clinical decisions

Team

  • Kyle Armour - Co-founder & Chief Executive Officer
  • David Rimm, M.D., Ph.D. - Co-founder & Chief Scientific Officer
    • Yale University faculty

Additional Research Findings

  • Near-instant molecular detection platform
  • No target amplification required
  • Multiplexed analyte detection
  • Point-of-care applications
  • New Haven, Connecticut headquarters
  • Founded in 2021
  • Yale University connection

Sources

Investors

NameLocationTypeStagesPortfolio
OMX VenturesSan Francisco, California, USAbiotech-focused
seedseries-a
23